TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+29.51%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$275M
AUM Growth
–
Cap. Flow
+$275M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
61.92%
Holding
65
New
65
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$25.6M |
| 2 |
Baxter International
BAX
|
$24M |
| 3 |
Medtronic
MDT
|
$23.9M |
| 4 |
AbbVie
ABBV
|
$20.7M |
| 5 |
Viatris
VTRS
|
$19.6M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 92.78% |
| 2 | Consumer Staples | 1.61% |
| 3 | Communication Services | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Curis
CRIS
$21.5M
| $2.95M | 1.07% |
+360,697
| New | +$2.95M |
|
27
Cardiff Oncology
CRDF
$129M
| $2.83M | 1.03% |
+157,403
| New | +$2.83M |
|
28
Syndax Pharmaceuticals
SNDX
$1.38B
| $2.64M | 0.96% |
+118,833
| New | +$2.64M |
|
|
MREO
29
Mereo BioPharma
MREO
$275M
| $2.61M | 0.95% |
+728,710
| New | +$2.61M |
|
|
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.7M | 0.62% |
+19,832
| New | +$1.7M |
|
|
ONCT
31
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $1.4M | 0.51% |
+285,714
| New | +$1.4M |
|
32
Cellectar Biosciences
CLRB
$15.4M
| $1.37M | 0.5% |
+658,373
| New | +$1.37M |
|
|
NMTR
33
DELISTED
9 Meters Biopharma, Inc. Common Stock
NMTR
| $1.2M | 0.43% |
+1,390,821
| New | +$1.2M |
|
34
Arcturus Therapeutics
ARCT
$465M
| $1.16M | 0.42% |
+26,722
| New | +$1.16M |
|
|
MYOV
35
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.13M | 0.41% |
+40,910
| New | +$1.13M |
|
36
Protara Therapeutics
TARA
$123M
| $950K | 0.35% |
+39,225
| New | +$950K |
|
37
Theravance Biopharma
TBPH
$694M
| $877K | 0.32% |
+49,373
| New | +$877K |
|
38
Neurocrine Biosciences
NBIX
$13.5B
| $688K | 0.25% |
+7,178
| New | +$688K |
|
39
Procter & Gamble
PG
$368B
| $447K | 0.16% |
+3,210
| New | +$447K |
|
40
BioXcel Therapeutics
BTAI
$52.8M
| $445K | 0.16% |
+9,630
| New | +$445K |
|
41
Mondelez International
MDLZ
$79.3B
| $386K | 0.14% |
+6,608
| New | +$386K |
|
42
Colgate-Palmolive
CL
$67.4B
| $371K | 0.13% |
+4,343
| New | +$371K |
|
|
CBAY
43
DELISTED
Cymabay Therapeutics
CBAY
| $356K | 0.13% |
+62,000
| New | +$356K |
|
44
Black Diamond Therapeutics
BDTX
$162M
| $330K | 0.12% |
+10,283
| New | +$330K |
|
45
Verizon
VZ
$184B
| $319K | 0.12% |
+5,437
| New | +$319K |
|
46
Costco
COST
$419B
| $317K | 0.12% |
+841
| New | +$317K |
|
47
Kimberly-Clark
KMB
$42.4B
| $309K | 0.11% |
+2,291
| New | +$309K |
|
48
Merck
MRK
$210B
| $297K | 0.11% |
+3,631
| New | +$297K |
|
49
Penumbra
PEN
$10.5B
| $297K | 0.11% |
+1,695
| New | +$297K |
|
50
Hormel Foods
HRL
$14B
| $287K | 0.1% |
+6,148
| New | +$287K |
|